CD274 and neoplasm: Azacytidine has shown promising effects when combined with immune checkpoint inhibitors, such as anti-PD-1 antibody (pembrolizumab), by promoting PD-L1 expression, and with anti-CTLA-4 antibody, by enhancing tumor recognition and response by T-cells [93].